Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05241223
Other study ID # OliveiraJM_PhD_FurlanettoKC
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 3, 2022
Est. completion date August 30, 2023

Study information

Verified date December 2023
Source Universidade Norte do Paraná
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aims of this study are to investigate the effectiveness of an online behavior change (BC) intervention in increasing physical activity (PA) and reducing sedentary behavior in adults with asthma, as well as, in improving other clinical outcomes, in short and medium term. In this single-blind randomized clinical trial, patients with clinically stable moderate to severe asthma, who are physically inactive and do not have cardiovascular and/or osteoneuromuscular impairments will be randomized into control (CG) or intervention (IG) groups (23 in each group). Both groups will carry out a minimum educational program. Additionally, the IG will receive weekly individual and/or group online sessions for 12 weeks of motivation-based BC intervention to promote PA and reduce sedentary behavior, based on both self-determination theory (SDT) and transtheoretical model (TTM). The IG will also receive a pedometer with specific strategies related to it. Both groups will be reassessed immediately after the intervention as well as 6 months after the end of the intervention. The primary outcomes are PA and sedentary behavior, which will be objectively assessed by a triaxial accelerometer (Actigraph wGT3X-BT). Secondary outcomes are: asthma control, functional capacity, quality of life, sleep quality and symptoms of anxiety and depression.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date August 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - people aged from 18 to 60 years - diagnosis of moderate to severe asthma, who underwent drug treatment for at least 6 months - clinical stability for at least 1 month (without hospitalizations, emergency care use or medication changes) - absence of cardiovascular and/or osteoneuromuscular diseases that could interfere/hinder the performance of tests and physical activity - absence of lung diseases other than asthma - preserved cognitive function - non-smokers or ex-smokers with <10 pack-years - report being physically inactive in accordance with current physical activity guidelines - able to make video calls through any platform and/or free app available Exclusion Criteria: - presence of any new orthopedic limitation that hinders the performance of physical activity during the study - perform =150 minutes per week of moderate to vigorous physical activity during the initial assessment

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Behavior change intervention
This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
Educational program
The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.

Locations

Country Name City State
Brazil Centro de Pesquisa e Pós Graduação na Unopar Londrina Paraná

Sponsors (1)

Lead Sponsor Collaborator
Universidade Norte do Paraná

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time spent in physical activity Time spent (in minutes and percentage of the day) in light-intensity and moderate to vigorous physical activities, measured by a triaxial activity monitor. 12 weeks from randomization
Primary Number of steps per day Number of steps per day measured by a triaxial activity monitor 12 weeks from randomization
Primary Time spent in sedentary behavior Time spent (in minutes and percentage of the day) in sedentary activities, measured by a triaxial activity monitor. 12 weeks from randomization
Secondary Time spent in physical activity Time spent (in minutes and percentage of the day) in light-intensity and moderate to vigorous physical activities, measured by a triaxial activity monitor. 36 weeks from randomization
Secondary Number of steps per day Number of steps per day measured by a triaxial activity monitor. 36 weeks from randomization
Secondary Time spent in sedentary behavior Time spent (in minutes and percentage of the day) in sedentary activities, measured by a triaxial activity monitor. 36 weeks from randomization
Secondary Asthma control Asthma Control Questionnaire score ranging from 0 to 6; the lower, the better. 12 weeks from randomization
Secondary Asthma control Asthma Control Questionnaire score ranging from 0 to 6; the lower, the better. 36 weeks from randomization
Secondary Asthma symptoms and exacerbations Frequency of asthma symptoms and exacerbations 12 weeks from randomization
Secondary Asthma symptoms and exacerbations Frequency of asthma symptoms and exacerbations 36 weeks from randomization
Secondary Asthma medication use Frequency of asthma rescue medication use 12 weeks from randomization
Secondary Asthma medication use Frequency of asthma rescue medication use 36 weeks from randomization
Secondary Incremental Step Test Number of steps climbed; the more the better 12 weeks from randomization
Secondary Incremental Step Test Number of steps climbed; the more the better 36 weeks from randomization
Secondary Sit-To-Stand test Number of repetitions in 1 minute; the more the better 12 weeks from randomization
Secondary Sit-To-Stand test Number of repetitions in 1 minute; the more the better 36 weeks from randomization
Secondary Timed Up-and-Go test Time to perform the test; the faster the better 12 weeks from randomization
Secondary Timed Up-and-Go test Time to perform the test; the faster the better 36 weeks from randomization
Secondary 4-Metre Gait Speed test Time to perform the test; the faster the better 12 weeks from randomization
Secondary 4-Metre Gait Speed test Time to perform the test; the faster the better 36 weeks from randomization
Secondary Quality of life score Asthma Quality of Life Questionnaire; ranges from 1 to 7 points; the higher the score, the better the quality of life 12 weeks from randomization
Secondary Quality of life score Asthma Quality of Life Questionnaire; ranges from 1 to 7 points; the higher the score, the better the quality of life 36 weeks from randomization
Secondary Sleep quality Subjectively measured by Pittsburgh Sleep Quality Index (score ranges from 0 to 21; the lower, the better) and objectively measured by Actiwatch 2 (Philips Respironics, Murrysville, Pennsylvania, USA). 12 weeks from randomization
Secondary Sleep quality Subjectively measured by Pittsburgh Sleep Quality Index (score ranges from 0 to 21; the lower, the better) and objectively measured by Actiwatch 2 (Philips Respironics, Murrysville, Pennsylvania, USA). 36 weeks from randomization
Secondary Anxiety and depression symptoms Hospital Anxiety and Depression Scale; ranges from 0 to 21 points; the higher the score, the worse the anxiety and depression symptoms 12 weeks from randomization
Secondary Anxiety and depression symptoms Hospital Anxiety and Depression Scale; ranges from 0 to 21 points; the higher the score, the worse the anxiety and depression symptoms 36 weeks from randomization
Secondary Basic psychological needs Basic Psychological Needs in Exercise Scale; ranges from 4 to 20; higher scores indicate greater levels of satisfaction of basic psychological needs 12 weeks from randomization
Secondary Basic psychological needs Basic Psychological Needs in Exercise Scale; ranges from 4 to 20; higher scores indicate greater levels of satisfaction of basic psychological needs 36 weeks from randomization
Secondary Motivational regulations Behavioral Regulation in Exercise Questionnaire; ranges from 0 to 4; the higher the score, the more regulated the individual is for a given level 12 weeks from randomization
Secondary Motivational regulations Behavioral Regulation in Exercise Questionnaire; ranges from 0 to 4; the higher the score, the more regulated the individual is for a given level 36 weeks from randomization
Secondary Lung function Spirometry determining the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and FEV1/FVC index. 12 weeks from randomization
Secondary Lung function Spirometry determining the forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and FEV1/FVC index. 36 weeks from randomization
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device